The combination of atezolizumab (anti-programmed death-ligand 1, PD-L1) and bevacizumab (anti-vascular endothelial growth factor, VEGF) antibodies demonstrated significantly better overall and progression-free survival than the kinase inhibitor sorafenib in patients with unresectable HCC in a phase III trial [4], and this combination was established as a first-line treatment for advanced HCC. This evidence concerns the gene CD274 and hepatocellular carcinoma.